Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Pharmasset, Inc. (NasdaqGS: VRUS) arising from its agreement for the Company to be acquired by Gilead Sciences, Inc. (Nasdaq:GILD).

Under the terms of the merger agreement, Gilead will commence a tender offer for all of the outstanding shares of Pharmasset's common stock for $137 per share in cash. The deal is expected to close during the first quarter of 2012, subject to customary conditions, including the tender of at least a majority of the outstanding Pharmasset shares.

Although Pharmasset currently has no products on the market, it has three clinical-stage product candidates for the treatment of hepatitis C, a health concern that is expected to worsen as the baby boomer generation ages. Pharmasset has been the best-performing biotech stock this year largely due to the excitement around these all-oral treatments, one of which is just entering the final stages of clinical trials.

Weiss & Lurie is investigating whether Pharmasset's Board acted in the best interests of its shareholders in approving the transaction given the imminence of the marketability of its products. If you own Pharmasset shares and would like more information about your rights as a shareholder or additional information concerning our investigation, please contact Michael A. Rogovin either by email at info@weisslurie.com or by telephone at (888) 593-4771.

Weiss & Lurie has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded institutions and individuals and obtained important corporate governance in these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or issuing materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at info@weisslurie.com or fill out the form on our website, http://www.weisslurie.com/contact/report_fraud/.

Attorney Advertising. Past results do not guarantee a similar outcome.

Weiss & Lurie
Michael A. Rogovin, Esq.
1500 Broadway, 16th Floor
New York, NY 10036
T: 212-682-3025
F: 212-682-3010
www.weisslurie.com
info@weisslurie.com